产品
编 号：F741930
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1005389-60-5
产品详情
生物活性：
Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo.
体内研究：
Dalotuzumab (h7C10; i.p.; 第一次 250 μg/小鼠，然后每周两次 125 μg/小鼠，持续 40 天) 显示对 MCF-7 和 A549 异种移植肿瘤模型的抗肿瘤作用。Animal Model:Swiss Nude mice (MCF-7 and A549 xenograft tumor models).
Dosage:125 and 250 (first time) μg/mice
Administration:Intraperitoneal injection; 250 μg/mice for the first time, then 125 μg/mice twice weekly for 40 days
Result:Led to average tumor volume at 6 weeks post-cell injection was reduced by 70% and 72% in the MCF-7 and A549 models, respectively.
体外研究：
Dalotuzumab (h7C10; 33 nM; 24 h) 抑制 IGF-1 和 IGF-2 诱导的 MCF7 雌激素依赖性乳腺癌细胞增殖，IC50 值分别为 4.2 和 3.1 nM。Dalotuzumab (33 nM; 24 h) 在 IGF-1 诱导的 MCF7 细胞中，诱导周期停滞，并抑制 IGF-IR 和 IRS-1 的自磷酸化。Dalotuzumab 使 NK 细胞介导的 MCF7 和 A459 细胞的裂解率分别提高了 26% 和 25%。Dalotuzumab (MK-0646; 10 μg/mL; 24, 48 h) 消除 IGF1 在子宫内膜癌细胞中的抗凋亡作用。
Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo.
体内研究：
Dalotuzumab (h7C10; i.p.; 第一次 250 μg/小鼠，然后每周两次 125 μg/小鼠，持续 40 天) 显示对 MCF-7 和 A549 异种移植肿瘤模型的抗肿瘤作用。Animal Model:Swiss Nude mice (MCF-7 and A549 xenograft tumor models).
Dosage:125 and 250 (first time) μg/mice
Administration:Intraperitoneal injection; 250 μg/mice for the first time, then 125 μg/mice twice weekly for 40 days
Result:Led to average tumor volume at 6 weeks post-cell injection was reduced by 70% and 72% in the MCF-7 and A549 models, respectively.
体外研究：
Dalotuzumab (h7C10; 33 nM; 24 h) 抑制 IGF-1 和 IGF-2 诱导的 MCF7 雌激素依赖性乳腺癌细胞增殖，IC50 值分别为 4.2 和 3.1 nM。Dalotuzumab (33 nM; 24 h) 在 IGF-1 诱导的 MCF7 细胞中，诱导周期停滞，并抑制 IGF-IR 和 IRS-1 的自磷酸化。Dalotuzumab 使 NK 细胞介导的 MCF7 和 A459 细胞的裂解率分别提高了 26% 和 25%。Dalotuzumab (MK-0646; 10 μg/mL; 24, 48 h) 消除 IGF1 在子宫内膜癌细胞中的抗凋亡作用。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备